This clinical trial is for participants who have metastatic castration-resistant prostate cancer (mCRPC) and whose cancer progressed on or after they were previously treated with next-generation Hormonal Agent (NHA). Study of Investigational Drug, MK5684, in Participants with Metastatic Castration-Resistant Prostate Cancer Patient Summary This clinical trial is for participants who have metastatic castration-resistant prostate cancer (mCRPC) and whose cancer progressed on or after they were previously treated with a next-generation Hormonal Agent (NHA). This trial is comparing the...
Merck Patient Summaries
Omaha-003 Patient Summary – Metastatic Castration Resistant
This clinical trial is for participants who have metastatic castration-resistant prostate cancer (mCRPC) and failed to respond to drugs or surgery to block the testes from making hormones and after treatment with other drugs for prostate cancer. Study of Investigational Drug, MK5684, in Participants with Metastatic Castration-Resistant Prostate Cancer Patient Summary The Omaha-003 clinical trial is for participants who have metastatic castration-resistant prostate cancer (mCRPC) and failed to respond to drugs or surgery to block the testes from making hormones and after treatment with other...
I-DXd Patient Summary – Metastatic Castration Resistant
Phase 3 Study of I-DXd Versus Docetaxel in mCRPC (MK-2400-001/IDeate-Prostate01) Testing I-DXd alone versus docetaxel for people with metastatic castration-resistant prostate cancer (mCRPC) About This Study Metastatic castration-resistant prostate cancer is a cancer that has spread and no longer responds to hormone-lowering treatment. There is currently no cure, and more research is needed. Study Purpose Researchers seek to learn how safe I-DXd is and see how well it works compared to docetaxel, which is a standard treatment for mCRPC. About the Investigational Drug (I-DXd, MK-2400) I-DXd is...
IDeate/Prostate02 Patient Summary – Metastatic Castration Resistant
MK-2400-01A: Substudy of I-DXd-based Treatment Combinations or as Monotherapy in mCRPC Testing I-DXd alone or in combination with other treatments for people with metastatic castration-resistant prostate cancer (mCRPC). About This Study Metastatic castration-resistant prostate cancer is a cancer that has spread and no longer responds to hormone-lowering treatment. There is currently no cure, and more research is needed. Study Purpose Researchers seek to learn how safe I-DXd is, by itself or with other drugs, identify the best dose, and see how the cancer responds to treatment. About the...
